Study of new treatment plan for MAC lung infection
Part of Infections, Lungs & breathing clinical trials.
This study follows people with a newly diagnosed MAC lung infection (a specific type of mycobacterial disease) and tests how they do on the standard three-drug treatment plan. It may help researchers better understand outcomes and safety for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a newly diagnosed MAC lung infection (or it came back) that needs a three-drug antibiotic regimen
- You can sign an informed consent form to join the study
- You are well enough overall that the study team feels it is safe for you to participate
- You do not have current drug or alcohol misuse that could affect safety or your ability to follow the study
- You do not have HIV infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a shorter course of antibiotics works for people with a specific type of lung infection caused by Mycobacterium avium complex (MAC). It aims to find a treatment that is just as effective but easier to complete.
This trial tests whether the drug Contezolid can quickly kill the bacteria that cause MAC lung disease, a type of lung infection. It is for people who have not been treated for this infection in the last 3 months.
This study looks at whether cordyceps sinensis, a natural fungus, can help prevent a lung infection caused by MAC bacteria from returning. If you have finished treatment for MAC lung disease and your sputum tests are negative, you may be able to join.
This trial studies how much medicine is needed (based on lab results) to treat MAC lung disease, an infection in the lungs. If you already have MAC and are receiving the recommended core antibiotics, your care may help researchers link treatment details to lab measurements.
This trial compares a new, enhanced treatment approach with the standard care for people living with HIV who have a serious bacterial infection called disseminated MAC (Mycobacterium avium complex). The goal is to see if the enhanced strategy works better. You might benefit from participating if you have this infection and are about to start treatment.
This Phase 3 trial compares two antibiotics—clarithromycin and azithromycin—to treat lung infection caused by Mycobacterium avium complex (MAC). It may help by showing which antibiotic works better and is safer for people who need MAC treatment.
Hear when a new Mycobacterium Avium Complex Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.